Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new revision entry (v3.4.2) was added and an older revision (v3.4.1) was removed. The latest version also includes the 'Study Status' section in the history view.SummaryDifference0.3%

- Check20 days agoChange DetectedThe history shows a new revision entry for v3.4.1 and the deletion of the previous revision v3.4.0. It reflects an administrative update to the page's revision history.SummaryDifference0.1%

- Check27 days agoChange DetectedThe history page adds a glossary toggle and a legend for color-coded changes (green for additions, red for deletions) in the study record view, and updates the footer to Revision: v3.4.0 with minor text tweaks such as capitalization changes for 'No FEAR Act'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check42 days agoChange DetectedMinor platform version update reflected in the Record History page: Revision v3.3.4 added and Revision v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.3.3 appears on the page, and 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' are removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedThe page history now lists Revision: v3.3.2, replacing v3.2.0. This appears to be a routine system release update rather than a change to study content or user-facing functionality.SummaryDifference0.1%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.